Results 151 to 160 of about 246,840 (252)

Retrospective study of comparable survival after neoadjuvant versus adjuvant chemotherapy in cT1-2N0M0 triple-negative breast cancer. [PDF]

Breast Cancer Res Treat
Olsson M, Janeva S, Martikainen J, Tzikas AK, Karlsson P, Parris TZ.   +5 more
europepmc   +1 more source

Plant Virus Immunotherapy for HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

Advanced NanoBiomed Research, EarlyView.
Cowpea mosaic virus (CPMV) nanoparticles are safe and potent cancer immunotherapy candidates with strong immunomodulatory activity. CPMV activates innate immunity, which in turn drives adaptive immune responses and promotes durable, systemic antitumor effects.
Jessica Fernanda Affonso de Oliveira, Patrick Opdensteinen, Andrea Simms, Seongwon Jung, Giuliana P. Mognol, Hui Chen, Judith A. Varner, Nicole F. Steinmetz   +7 more
wiley   +1 more source

Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service. [PDF]

Br J Cancer
Hale J, Gilbert T, Stott M, Whelan P, Jackson R, Wong H, McKay M, Ghaneh P, Halloran C, Faluyi O, Dunne D, Neoptolemos JP, Palmer D.   +12 more
europepmc   +1 more source

Spatial Cell Death and Oxidative Stress Dynamics in Gas Plasma‐Treated Tumor Tissues

Advanced NanoBiomed Research, EarlyView.
Schematic representation of the four experimental models to study tissue penetration and oxidation. Four tissue models were used. Human pancreatic cancer cells were grown on the chorioallantois membrane of chicken embryos and gas plasma‐treated in ovo, murine colorectal tumor tissue was gas plasma‐exposed ex vivo, murine squamous cell carcinoma cells ...
Anke Schmidt, Shahrzad Rokhsary, Linus Hübner, Lea Miebach, Sander Bekeschus   +4 more
wiley   +1 more source

Adjuvant Chemotherapy in Lymph Node-Negative, T1 Triple-Negative Breast Cancer. [PDF]

Cancer Med
Anampa JD, Alvarez Soto A, Jimenez RB, Obeng-Gyasi S, Xue X.   +4 more
europepmc   +1 more source

Advances in Chitosan Nanoparticles: A Comprehensive Review of Properties, Synthesis, Characterization, Multidisciplinary Applications, and Future Perspectives

Journal of Applied Polymer Science, EarlyView.
This review highlights the synthesis of chitosan nanoparticles from natural sources, the thorough characterization of them, and use of microscopic and spectroscopic methods. It emphasizes that it has some indispensable properties such as being non‐toxic, antimicrobial, and capable of controlled drug release.
Mariam Sohail Mansoor, Nayab Raza, Furqana Bibi, Madiha Mumtaz, Asif Abbas, Farasat Haider, Basit Ali   +6 more
wiley   +1 more source

Efficacy of Adjuvant Chemotherapy for T1-2 Stage III Colorectal Cancer. [PDF]

Cancers (Basel)
Maeda H, Oba K, Kashiwabara K, Aoyama T, Mayanagi S, Kanda M, Honda M, Muto M, Sakamoto J, Yamagishi H, Yoshikawa T.   +10 more
europepmc   +1 more source

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative. [PDF]

Front Oncol
Wei Y, Wang M, Huang Y, Gan L, Li K, Li Y, Li Z, Cheng Q.   +7 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source